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ABSTRACT. The growth of the murine myelomonocytic leukemia tumor, WEHI3B, has been shown to be 
inhibited by a two-step treatment: first, incubation for one hour with either interleukin-1 (human recombinant 
IL-lo or tumor necrosis factor (human recombinant TNP-ar); second, subsequent exposure to prostaglandins. 
Preincubation with IL-1 rendered the tumor cells more susceptible to subsequent treatment with either 
prostaglandin E2 or to the stable synthetic analogue of prostacyclin DC-PG12. Preincubation with TNP-ar 
rendered the tumor cells more susceptible to further treatment with PGEz but not with DC-PG12. 
Preconditioning of the tumour cells with either IL-lo or TNF’a. did not affect cytostasis by subsequent culture 
of tumor cells in presence of either one of the cytokines. It is concluded that the interactions between 
macrophage cytokines and prostaglandhts in enhancement of antitumor activity might imply first binding or 
induction of certain modifications in the tumor cells by the cytokines which render the cells more susceptible 
to exposure to prostaglandins. 
INTRODUCTION 
Interleukin-1 (IL-l; for review see (1) ) and Tumor 
Necrosis Factor (TNF-a; for review see (2) ), are 
cytokine products of macrophages expressing a wide 
array of biological activities, including antitumor ac- 
tivity (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13). 
Occurrence of interactions between macrophage 
cytokines and products of arachidonic acid (AA), is 
well documented. Thus, inhibitors of the 
cyclooxygenase pathway of AA as indomethacin, 
augment LPS-induced IL-l response (14). Addition 
of exogenous prostaglandins uppress production of 
IL-l by macrophages (14). IL-l induction of IL-2 re- 
quires participation of metabolic intermediates 
governed by 5-lipoxygenase activity (15). Release of 
TNFa from macrophages was found to be regulated 
by PGEz (16). The interaction between AA 
products (eicosanoids; prostaglandins and 
leukotrienes), was also expressed in respect to an- 
titumor activity. Thus, indomethacin inhibited 
partially the effect of IL-l on monocyte-mediated 
antitumor cytotoxicity, whereas pretreatment of 
monocytes with prostaglandin resulted in increase of 
monocyte cytotoxicity (7). We reported (3), that ex- 
ogenous PGE?, enhances and leukotriene C4 inhibits 
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IL-l activity against WEHI3B tumor cells. Interac- 
tion between the two cytokines, IL-l and TNFa was 
also reported (6) as expressed by an additive effect 
in destruction of tumor cells. 
The synergistic effect of IL-l and PGE2 in inhi- 
bition of WEHI-3B cell growth was demonstrated 
by us when IL-l and PGE:! were added simul- 
taneously to tumor-cell cultures at the beginning of 
the incubation time (3). The aim of the present 
work was to determine if the synergistic antitumor 
cytostatic effect of a cytokine-prostaglandin com- 
bination is also exhibited when tumor cells are first 
treated with the macrophage cytokine and sub- 
sequently exposed to exogenous prostaglandin. 
MATERIALS AND METHODS 
Materials 
Recombinant human interleukin-1 (HrIL-l), was a 
gift from Dr. S. Gillis, IMMUNEX (Seattle, 
Washington, USA). Recombinant Human Tumor 
Necrosis Factor (HrTNF-a) was a gift from Dr. W. 
Fiers, University of Ghent, Belgium. Prostaglandin 
E_ (PGQ) and the stable synthetic analogue of 
prostacyclin (DC-PGI,; 5E-13,14-didehydro-carbo- 
prostacyclin), were purchased from Sigma 
Chemicals Co. (St. Louis, MO, USA). HrIL-la! and 
HrTNFa concentrations are given in arbitrary 
units; 100 U IL-ldml=l ng/ml; 1 U TNF- 
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dml=O. 1 ng/ml). Complete medium included 
RPMI-1640 medium (GIBCO, Grand Island, NY, 
USA), fetal calf serum (Sambio b.v., Uden, Hol- 
land), penicillin-streptomycin mixture and, 
glutamine and bicarbonate from Flow Lab. (Irvine, 
UK). 3H-thymidirre (3HdT) was ordered from 
Amersham International (Amersham, UK). All 
tissue-culture reagents and plastics were bought 
presterilized. 
Effect of cytokines and prostaglandins on 
WEHI-3B growth 
WEHI-3B tumor cells were cultured (37°C 7.5% 
COZ) in 25cm3 as previously described (17). Brief- 
ly, WEHI-3B (lo3 cells/l00 ~1 complete medium), 
were incubated in 96-well multiwell dishes for 24 h. 
3HdT (0.5 &i/50 ,ul/well), was than added and the 
multiwell dishes were. incubated for further 18 h 
period. The cells were harvested and the incor- 
porated radioactivity counted in a scintillation 
counter. The cytostatic effect of cytokines and pros- 
taglandins on WEHI3B growth (inhibition of 3HdT 
incorporation) was determined under two ex- 
perimental conditions; first, pretreatment with 
cytokine for one hour at 37°C washing and sub- 
sequent addition of prostaglandin or cytokine at the 
beginning of 42 h incubation time; second, simul- 
taneous addition at the beginning of incubation time 
of cytokine and prostaglandin either alone or in 
various combinations. Each prostaglandin and 
cytokine was added in a volume of 25 pi/well. 
Controls of WEHI-3B cells alone were* supple- 
mented with an appropriate volume of medium 
only. Each kind of treatment and controls were 
done in 5 parallel samples and each experiment was 
repeated at least 3 times with similar results. Stock 
solutions of PGE2 and DC-PGIz in ethanol, were 
diluted to final concentrations in complete medium. 
The final concentration of ethanol in each well was 
proven to have no effect on WEHI-3B growth. 
RESULTS 
Effect of simultaneous addition of cytokines and 
prostaglandins on WEHI3B growth 
We confirmed previous results (3) showing syner- 
gistic effect of IL-l and PGEz in inhibition of 
WEHI-3B cell growth (results not shown here). A 
similar synergistic effect was now found between IL- 
1 and PGI;! (Fig. 1). 
TNFar alone was cytostatic at a high dose of 
1000 U/ml and this effect was additively reinforced 
by simultaneous addition of ILt, (100 U/ml) (Fig. 
2). A synergistic cytostatic effect was shown to 
occur between TNFa (1000 U/ml) and 100 ng/ml 
PGE;? (Fig. 3). On the other hand, no such syner- 
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Fig. 1 Cytostatic effect on WEHI3B cells of simultaneous 
addition of IL,, and PGIz at the beginning of incubation time. 
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Fig. 2 Cytostatic effect on WEHI3B of simultaneous 
addition of IL,, and TNFa at the beginning of incubation 
time. 
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Fig. 3 Cytostatic effect on WEHI3B cells of simultaneous 
addition of TNFa and PGI, at the beginning of incubation 
time. 
gistic effect was observed in a combination of~TNFa 
(1000 U/ml) and PGI:! (1.25 or 12.5 ng/ml; Fig. 4). 
Quantities of PG12 higher than 12.5 &ml were 
markedly cytostatic; 75% and 91% inhibition of 
3HdT incorporation for PG12 125 and 1250 ng/ml, 
respectively). 
Effect of pretreatment with IL-la or TNFar on 
subsequent exposure to prostaglandins 
Pretreatment with ILi, (100 U/ml) increased cytos- 
tasis by subsequent exposure of WEHI-3B cells to 
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Fig. 4 Cytostatic effect on WEHI-3B cells simultaneous 
addition of TNFar and PGI, at the beginning of incubation 
time; same suspension of WEHI3B cells was used as in exp. 
brought in Fig. 3; cytostatic c%ct of TNFar alone is given for 
comparison. 
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Fig. 6 Cytostatic effect on WEHI3B cells of prior treatment 
with IL,, (100 U/ml) on subsequent reatment with PGI, (A 
= no subsequent reatment; B = PG&, 12.5 ng/ml). 
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Fig. 5 Cytostatic effect on WEHI9B cells of prior treatment 
with IL-1 (100 U/ml in A, B, C, D; 10 U/ml in E, F) on 
subsequent reatment with PGE, (A and E = no subsequent 
treatment; B and F = PGE,, 1000 &ml; C = PGE,, 
100 ng/ml; D = PGE,, 10 &ml). 
PGEz (10-1000 ng/ml). The effect was also evident 
by pretreatment with 10 U/ml IL1, (Fig. 5). 
Pretreatment with ILi, (100 U/ml) increased also 
cytostasis by subsequent exposure of WEHI-3B cells 
to PG12, 12.5 ng/ml (Fig. 6). 
Prior treatment with TNFa: (1000 U/ml), 
rendered the WEHI3B cells susceptible to sub- 
sequent treatment with PGE* but not to subsequent 
treatment with PG12 (Fig. 7). 
Effect of pretreatment with IL-1 or TNF on 
subsequent exposure to the same or to the 
unrelated cytokine 
Pretreatment with IL-la (100 U/ml), had no effect 
on subsequent exposure to either ILCY itself or to 
TNFIx (Fig. 8). Pretreatment with TNFar did also 
not affect cytostasis toward WEHI-3B cells by sub- 
sequent exposure to either TNFa or to IL-la: (Fig. 
8). Prior treatment with either one of the cytokines 
without subsequent exposure did not affect ap- 
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Fig. 7 Cytostatic effect on WEHI3B cells of prior treatment 
with TNFu (1000 U/ml) on subsequent reatment with PG’s 
(A = no subsequent reatment; B = PGE,, 1000 ng/ml; 
C = PGE,, 100 &ml; D = PGI,, 12.5 &ml; E = PGI,, 
12.5 ng/ml). 
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Fig. 8 Cytostatic effect on WEHI3B cells of prior treatment 
with IL,, (100 U/ml) or TNFo (1000 U/ml) on subsequent 
treatment with either IL,, (100 U/ml) or TNFor (1000 U/ml) 
(A = TNFo; B = IL,,; C = TNFa + IL,,; D = no 
subsequent reatment). 
preciably thymidine incorporation by WEHI3B 
tumor cells (Fig. 8). 
All the experiments performed with IL-la were 
repeated with IL-ll3 with similar results (Data not 
shown here). 
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DISCUSSION 
We have reported (3), that the cytostatic effect of 
HrIL-1 toward WEHI-3B tumor cells was enhanced 
by simultaneous addition of PGE2 to tumor-cell cul- 
tures. A similar synergistic effect was now found by 
simultaneous addition of IL-l and PGI*. Another 
macrophage cytokine, HrTNFa, was also synergistic 
with PGE2 in respect to cytostatic activity against 
WEHI-3B tumor cells. However, unlike IL-l, the 
cytostatic effect of TNF~x was not enhanced by the 
prostacyclin PGI*. It should be noted that TNFu on 
a dose comparable basis, was less cytostatic for 
WEHI-3B cells than IL-l. It is also possible that the 
difference found now between the two cytokines in 
respect to their interaction with PGE2 or PG12, 
could be attributed to differences in the mode of 
action between the two prostaglandins. Differences 
between PGE;! and PG12, in their activity were 
described previously. Thus, while mouse resident 
peritoneal macrophages timulated in vitro by LPS, 
produced both PGEz and PGI2, only PGE2 had a 
negative regulatory effect on macrophage activation 
for tumor-cell killing (18). It was also reported that 
PGEZ was more effective than PG12 for inhibition 
of granulomatous inflammation (19). 
It has been reported (2, 11,20,21,22) that a pre- 
requisite of antitumor activity of cytokines is their 
binding to cell-surface receptors. In view of this as- 
sumption, we sought to determine if pretreatment 
of WEHI3B tumor cells with macrophage cytokines 
will render them more susceptible to subsequent ex- 
posure to prostaglandins. we found now that the 
synergy in cytostatic effect toward WEHI-3B cells 
between IL-l and PGE;! or PG12 and between TNFar 
and PGE2, was also evident when WEHI-3B were 
first put in contact with the cytokine, washed and 
than cultured in presence of the prostaglandin. As 
in the case of simultaneous addition, pretreatment 
with TNFa( did not render the WEHI-3B tumor cells 
more susceptible to subsequent exposure to PGIz. 
It has been reported (3) that WEHI-3B tumor cells, 
unlike other WEHI lines (23,24), do not synthesize 
eicosanoids when stimulated with the calcium 
ionophore A23187. Accordingly, release of 
eicosanoids by WEHI-3B cells do not play a role in 
the enhancement of cytostatic effect of cytokines by 
prostaglandins. 
The interrelationship between macrophage 
cytokines and arachidonic acid metabolites is well 
documented in respect to involvement of AA meta- 
bolites in induction of cytokine production (14, 16, 
25, 26), and to modulation of cytokine activities by 
AA metabolites (15, 27). However, the mechanism 
of synergy between cytokines and AA products in 
their antitumor activity, is not yet clear. Some pos- 
sibilities can be considered; a) pretreatment with 
either IL-l or TNFar might induce increase in the 
total number of cell surface receptors for pros- 
taglandins. Such a possibility was considered in 
respect to regulation of binding of TNFa by treat- 
ment of cells with t-interferon (20). b) pretreatment 
with a macrophage cytokine of WEHI-3B tumor 
cells might induce some damage which render the 
cells more susceptible to subsequent contact with 
prostaglandins. 
It should be noted that pretreatment with either 
one of the cytokines did not render the WEHI-3B 
tumor cells more susceptible to a second exposure 
to cytokines. It could be that prior binding of 
cytokines to cell receptors prevents binding to the 
tumor cells of subsequently added cytokines. It has 
been also claimed (28) that pretreatment with IL-l 
down regulates cellular response to TNFa by induc- 
ing decrease in the number of receptors for TNFa. 
In conclusion, our present results indicate that the 
interaction between macrophage cytokines and 
prostaglandins in enhancement of antitumor ac- 
tivity, might imply first binding or induction of 
certain modifications in the tumor cells by the 
macrophage cytokiae resulting in increased 
susceptlbiiity to subsequent exposure to prostaglan- 
dins. 
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